Advertisement

C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond

  • James D. McFadyenEmail author
  • Johannes Zeller
  • Lawrence A. Potempa
  • Geoffrey A. Pietersz
  • Steffen U. Eisenhardt
  • Karlheinz PeterEmail author
Chapter
Part of the Subcellular Biochemistry book series (SCBI, volume 94)

Abstract

C-reactive protein (CRP) is an evolutionary highly conserved member of the pentraxin superfamily of proteins. CRP is widely used as a marker of inflammation, infection and for risk stratification of cardiovascular events. However, there is now a large body of evidence, that continues to evolve, detailing that CRP directly mediates inflammatory reactions and the innate immune response in the context of localised tissue injury. These data support the concept that the pentameric conformation of CRP dissociates into pro-inflammatory CRP isoforms termed pCRP* and monomeric CRP. These pro-inflammatory CRP isoforms undergo conformational changes that facilitate complement binding and immune cell activation and therefore demonstrate the ability to trigger complement activation, activate platelets, monocytes and endothelial cells. The dissociation of pCRP occurs on the surface of necrotic, apoptotic, and ischaemic cells, regular β-sheet structures such as β-amyloid, the membranes of activated cells (e.g., platelets, monocytes, and endothelial cells), and/or the surface of microparticles, the latter by binding to phosphocholine. Therefore, the deposition and localisation of these pro-inflammatory isoforms of CRP have been demonstrated to amplify inflammation and tissue damage in a broad range of clinical conditions including ischaemia/reperfusion injury, Alzheimer’s disease, age-related macular degeneration and immune thrombocytopaenia. Given the potentially broad relevance of CRP to disease pathology, the development of inhibitors of CRP remains an area of active investigation, which may pave the way for novel therapeutics for a diverse range of inflammatory diseases.

Keywords

C-reactive protein CRP Inflammation Complement CRP structure Ischaemia/reperfusion injury Alzheimer’s disease Atherosclerosis 

Notes

Acknowledgements

We thank Eliana Stanziano for her excellent manuscript editing and formatting.

References

  1. Agrawal A, Volanakis JE (1994) Probing the C1q-binding site on human C-reactive protein by site-directed mutagenesis. J Immunol Baltim Md 1950 152:5404–5410Google Scholar
  2. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE (2001) Topology and structure of the C1q-binding site on C-reactive protein. J Immunol Baltim Md 1950 166:3998–4004.  https://doi.org/10.4049/jimmunol.166.6.3998CrossRefGoogle Scholar
  3. Agrawal A, Simpson MJ, Black S et al (2002) A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol Baltim Md 1950 169:3217–3222.  https://doi.org/10.4049/jimmunol.169.6.3217CrossRefGoogle Scholar
  4. Agrawal A, Cha-Molstad H, Samols D, Kushner I (2003a) Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 108:539–547.  https://doi.org/10.1046/j.1365-2567.2003.01608.xCrossRefPubMedPubMedCentralGoogle Scholar
  5. Agrawal A, Samols D, Kushner I (2003b) Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter. Mol Immunol 40:373–380.  https://doi.org/10.1016/s0161-5890(03)00148-2CrossRefPubMedGoogle Scholar
  6. Anderson HC, McCarty M (1950) Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever. Am J Med 8:445–455.  https://doi.org/10.1016/0002-9343(50)90226-9CrossRefPubMedGoogle Scholar
  7. Armstrong PB (2015) Comparative biology of the pentraxin protein family: evolutionarily conserved component of innate immune system. Int Rev Cell Mol Biol 316:1–47.  https://doi.org/10.1016/bs.ircmb.2015.01.002CrossRefPubMedGoogle Scholar
  8. Ash R (1933) Nonspecific precipitins for pneumococcic fraction C in acute infections. J Infect Dis 53:89–97CrossRefGoogle Scholar
  9. Baltz ML, de Beer FC, Feinstein A et al (1982) Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci 389:49–75.  https://doi.org/10.1111/j.1749-6632.1982.tb22125.xCrossRefPubMedGoogle Scholar
  10. Bang R, Marnell L, Mold C et al (2005) Analysis of binding sites in human C-reactive protein for FcγRI, FcγRIIA, and C1q by site-directed mutagenesis. J Biol Chem 280:25095–25102.  https://doi.org/10.1074/jbc.M504782200CrossRefPubMedGoogle Scholar
  11. Black S, Agrawal A, Samols D (2003) The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct. Mol Immunol 39:1045–1054.  https://doi.org/10.1016/s0161-5890(03)00031-2CrossRefPubMedGoogle Scholar
  12. Braig D, Kaiser B, Thiele JR et al (2014) A conformational change of C-reactive protein in burn wounds unmasks its proinflammatory properties. Int Immunol 26:467–478.  https://doi.org/10.1093/intimm/dxu056CrossRefPubMedGoogle Scholar
  13. Braig D, Nero TL, Koch H-G et al (2017) Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites. Nat Commun 8:14188.  https://doi.org/10.1038/ncomms14188CrossRefPubMedPubMedCentralGoogle Scholar
  14. Calabro P, Chang DW, Willerson JT, Yeh ETH (2005) Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 46:1112–1113.  https://doi.org/10.1016/j.jacc.2005.06.017CrossRefPubMedGoogle Scholar
  15. Chirco KR, Whitmore SS, Wang K et al (2016) Monomeric C-reactive protein and inflammation in age-related macular degeneration. J Pathol 240:173–183.  https://doi.org/10.1002/path.4766CrossRefPubMedPubMedCentralGoogle Scholar
  16. de Beer FC, Hind CR, Fox KM et al (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47:239–243.  https://doi.org/10.1136/hrt.47.3.239CrossRefPubMedPubMedCentralGoogle Scholar
  17. de la Torre R, Peña E, Vilahur G et al (2013) Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition. J Thromb Haemost JTH 11:2048–2058.  https://doi.org/10.1111/jth.12415CrossRefPubMedGoogle Scholar
  18. Edwards AO, Ritter R, Abel KJ et al (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308:421–424.  https://doi.org/10.1126/science.1110189CrossRefPubMedGoogle Scholar
  19. Eisenhardt SU, Habersberger J, Murphy A et al (2009) Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 105:128–137.  https://doi.org/10.1161/CIRCRESAHA.108.190611CrossRefPubMedGoogle Scholar
  20. Elices MJ, Osborn L, Takada Y et al (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577–584.  https://doi.org/10.1016/0092-8674(90)90661-wCrossRefPubMedGoogle Scholar
  21. Eltzschig HK, Eckle T (2011) Ischemia and reperfusion–from mechanism to translation. Nat Med 17:1391–1401.  https://doi.org/10.1038/nm.2507CrossRefPubMedGoogle Scholar
  22. Friedman DS, O’Colmain BJ, Muñoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol Chic Ill 1960 122:564–572.  https://doi.org/10.1001/archopht.122.4.564CrossRefGoogle Scholar
  23. Fujita M, Takada YK, Izumiya Y, Takada Y (2014) The binding of monomeric C-reactive protein (mCRP) to integrins αvβ3 and α4β1 is related to its pro-inflammatory action. PLoS ONE 9:e93738.  https://doi.org/10.1371/journal.pone.0093738CrossRefPubMedPubMedCentralGoogle Scholar
  24. Gaboriaud C, Juanhuix J, Gruez A et al (2003) The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 278:46974–46982.  https://doi.org/10.1074/jbc.M307764200CrossRefPubMedGoogle Scholar
  25. Ganter U, Arcone R, Toniatti C et al (1989) Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773–3779CrossRefGoogle Scholar
  26. Griselli M, Herbert J, Hutchinson WL et al (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733–1740.  https://doi.org/10.1084/jem.190.12.1733CrossRefPubMedPubMedCentralGoogle Scholar
  27. Habersberger J, Strang F, Scheichl A et al (2012) Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res 96:64–72.  https://doi.org/10.1093/cvr/cvs237CrossRefPubMedGoogle Scholar
  28. Hausenloy DJ, Yellon DM (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123:92–100.  https://doi.org/10.1172/JCI62874CrossRefPubMedPubMedCentralGoogle Scholar
  29. Holers VM (2014) Complement and its receptors: new insights into human disease. Annu Rev Immunol 32:433–459.  https://doi.org/10.1146/annurev-immunol-032713-120154CrossRefPubMedGoogle Scholar
  30. Hurlimann J, Thorbecke GJ, Hochwald GM (1966) The liver as the site of C-reactive protein formation. J Exp Med 123:365–378.  https://doi.org/10.1084/jem.123.2.365CrossRefPubMedPubMedCentralGoogle Scholar
  31. Iwamoto N, Nishiyama E, Ohwada J, Arai H (1994) Demonstration of CRP immunoreactivity in brains of Alzheimer’s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 177:23–26.  https://doi.org/10.1016/0304-3940(94)90035-3CrossRefPubMedGoogle Scholar
  32. Jabs WJ, Lögering BA, Gerke P et al (2003) The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 33:152–161.  https://doi.org/10.1002/immu.200390018CrossRefPubMedGoogle Scholar
  33. Ji S-R, Wu Y, Potempa LA et al (2006) Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26:935–941.  https://doi.org/10.1161/01.ATV.0000206211.21895.73CrossRefPubMedGoogle Scholar
  34. Ji S-R, Wu Y, Zhu L et al (2007) Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J Off Publ Fed Am Soc Exp Biol 21:284–294.  https://doi.org/10.1096/fj.06-6722comCrossRefGoogle Scholar
  35. Jones NR, Pegues MA, McCrory MA et al (2012) A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in C-reactive protein Transgenic Mice and Humans. Mol Ther Nucleic Acids 1:e52.  https://doi.org/10.1038/mtna.2012.44CrossRefPubMedPubMedCentralGoogle Scholar
  36. Ji S-R, Ma L, Bai C-J et al (2009) Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J Off Publ Fed Am Soc Exp Biol 23:1806–1816.  https://doi.org/10.1096/fj.08-116962CrossRefGoogle Scholar
  37. Kapur R, Heitink-Pollé KMJ, Porcelijn L et al (2015) C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia. Blood 125:1793–1802.  https://doi.org/10.1182/blood-2014-05-579110CrossRefPubMedGoogle Scholar
  38. Khreiss T, József L, Potempa LA, Filep JG (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109:2016–2022.  https://doi.org/10.1161/01.CIR.0000125527.41598.68CrossRefPubMedGoogle Scholar
  39. Khreiss T, József L, Potempa LA, Filep JG (2005) Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 97:690–697.  https://doi.org/10.1161/01.RES.0000183881.11739.CBCrossRefPubMedGoogle Scholar
  40. Kobayashi S, Inoue N, Ohashi Y et al (2003) Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 23:1398–1404.  https://doi.org/10.1161/01.ATV.0000081637.36475.BCCrossRefPubMedGoogle Scholar
  41. Kresl JJ, Potempa LA, Anderson BE (1998) Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 30:1415–1426.  https://doi.org/10.1016/s1357-2725(98)00078-8CrossRefPubMedGoogle Scholar
  42. Kuta AE, Baum LL (1986) C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 164:321–326.  https://doi.org/10.1084/jem.164.1.321CrossRefPubMedGoogle Scholar
  43. Lane T, Wassef N, Poole S et al (2014) Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res 114:672–676.  https://doi.org/10.1161/CIRCRESAHA.114.302770CrossRefPubMedGoogle Scholar
  44. Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6A):9S–16S.  https://doi.org/10.1016/j.amjmed.2004.02.006CrossRefPubMedGoogle Scholar
  45. Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424.  https://doi.org/10.1056/NEJM199408183310701CrossRefPubMedGoogle Scholar
  46. Lu J, Marnell LL, Marjon KD et al (2008) Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 456:989–992.  https://doi.org/10.1038/nature07468CrossRefPubMedPubMedCentralGoogle Scholar
  47. Lv J-M, Wang M-Y (2018) In vitro generation and bioactivity evaluation of C-reactive protein intermediate. PLoS ONE 13:e0198375.  https://doi.org/10.1371/journal.pone.0198375CrossRefPubMedPubMedCentralGoogle Scholar
  48. Massberg S, Enders G, Matos FC et al (1999) Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 94:3829–3838CrossRefGoogle Scholar
  49. Masters CL, Bateman R, Blennow K et al (2015) Alzheimer’s disease. Nat Rev Dis Primer 1:15056.  https://doi.org/10.1038/nrdp.2015.56CrossRefGoogle Scholar
  50. McCarty M (1982) Historical perspective on C-reactive protein. Ann N Y Acad Sci 389:1–10.  https://doi.org/10.1111/j.1749-6632.1982.tb22121.xCrossRefPubMedGoogle Scholar
  51. McFadyen JD, Kiefer J, Braig D et al (2018) Dissociation of C-reactive protein localizes and amplifies inflammation: evidence for a direct biological role of C-reactive protein and its conformational changes. Front Immunol 9:1351.  https://doi.org/10.3389/fimmu.2018.01351CrossRefPubMedPubMedCentralGoogle Scholar
  52. Mihlan M, Stippa S, Józsi M, Zipfel PF (2009) Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 16:1630–1640.  https://doi.org/10.1038/cdd.2009.103CrossRefPubMedGoogle Scholar
  53. Mihlan M, Blom AM, Kupreishvili K et al (2011) Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J Off Publ Fed Am Soc Exp Biol 25:4198–4210.  https://doi.org/10.1096/fj.11-186460CrossRefGoogle Scholar
  54. Molins B, Peña E, de la Torre R, Badimon L (2011) Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res 92:328–337.  https://doi.org/10.1093/cvr/cvr226CrossRefPubMedGoogle Scholar
  55. Nguyen NY, Suzuki A, Cheng SM et al (1986) Isolation and characterization of Limulus C-reactive protein genes. J Biol Chem 261:10450–10455PubMedGoogle Scholar
  56. O’Flynn J, van der Pol P, Dixon KO et al (2016) Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin. Am J Physiol Renal Physiol 310:F1308–F1316.  https://doi.org/10.1152/ajprenal.00645.2014CrossRefPubMedGoogle Scholar
  57. Osmand AP, Friedenson B, Gewurz H et al (1977) Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A 74:739–743.  https://doi.org/10.1073/pnas.74.2.739CrossRefPubMedPubMedCentralGoogle Scholar
  58. Pathak A, Agrawal A (2019) Evolution of C-reactive protein. Front Immunol 10:943.  https://doi.org/10.3389/fimmu.2019.00943CrossRefPubMedPubMedCentralGoogle Scholar
  59. Pegues MA, McCrory MA, Zarjou A, Szalai AJ (2013) C-reactive protein exacerbates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 304:F1358–F1365.  https://doi.org/10.1152/ajprenal.00476.2012CrossRefPubMedPubMedCentralGoogle Scholar
  60. Pepys MB (2005) CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 25:1091–1094.  https://doi.org/10.1161/01.ATV.0000169644.88847.28CrossRefPubMedGoogle Scholar
  61. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805–1812.  https://doi.org/10.1172/JCI18921CrossRefPubMedPubMedCentralGoogle Scholar
  62. Pepys MB, Dash AC, Fletcher TC et al (1978) Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature 273:168–170.  https://doi.org/10.1038/273168a0CrossRefPubMedGoogle Scholar
  63. Pepys MB, Hawkins PN, Kahan MC et al (2005) Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 97:e97–103.  https://doi.org/10.1161/01.RES.0000193595.03608.08CrossRefPubMedPubMedCentralGoogle Scholar
  64. Pepys MB, Hirschfield GM, Tennent GA et al (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217–1221.  https://doi.org/10.1038/nature04672CrossRefPubMedGoogle Scholar
  65. Potempa LA, Maldonado BA, Laurent P et al (1983) Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol 20:1165–1175.  https://doi.org/10.1016/0161-5890(83)90140-2CrossRefPubMedGoogle Scholar
  66. Ramage L, Proudfoot L, Guy K (2004) Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles. Inhal Toxicol 16:607–613.  https://doi.org/10.1080/08958370490464599CrossRefPubMedGoogle Scholar
  67. Ridker PM (2004) High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 148:S19–S26.  https://doi.org/10.1016/j.ahj.2004.04.028CrossRefPubMedGoogle Scholar
  68. Ridker PM (2009) C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 55:209–215.  https://doi.org/10.1373/clinchem.2008.119214CrossRefPubMedGoogle Scholar
  69. Ridker PM, Cushman M, Stampfer MJ et al (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979.  https://doi.org/10.1056/NEJM199704033361401CrossRefPubMedGoogle Scholar
  70. Ridker PM, Buring JE, Shih J et al (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733.  https://doi.org/10.1161/01.cir.98.8.731CrossRefPubMedGoogle Scholar
  71. Ridker PM, Danielson E, Fonseca FAH et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207.  https://doi.org/10.1056/NEJMoa0807646CrossRefPubMedGoogle Scholar
  72. Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131.  https://doi.org/10.1056/NEJMoa1707914CrossRefPubMedGoogle Scholar
  73. Ridker PM, MacFadyen JG, Everett BM et al (2018) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet Lond Engl 391:319–328.  https://doi.org/10.1016/S0140-6736(17)32814-3CrossRefGoogle Scholar
  74. Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126.  https://doi.org/10.1056/NEJM199901143400207CrossRefPubMedPubMedCentralGoogle Scholar
  75. Scheltens P, Blennow K, Breteler MMB et al (2016) Alzheimer’s disease. Lancet Lond Engl 388:505–517.  https://doi.org/10.1016/S0140-6736(15)01124-1CrossRefGoogle Scholar
  76. Seddon JM, George S, Rosner B, Rifai N (2005) Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol Chic Ill 1960 123:774–782.  https://doi.org/10.1001/archopht.123.6.774CrossRefGoogle Scholar
  77. Semple JW, Italiano JE, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11:264–274.  https://doi.org/10.1038/nri2956CrossRefPubMedGoogle Scholar
  78. Shrive AK, Cheetham GM, Holden D et al (1996) Three dimensional structure of human C-reactive protein. Nat Struct Biol 3:346–354.  https://doi.org/10.1038/nsb0496-346CrossRefPubMedGoogle Scholar
  79. Singh SK, Thirumalai A, Pathak A et al (2017) Functional transformation of C-reactive protein by hydrogen peroxide. J Biol Chem 292:3129–3136.  https://doi.org/10.1074/jbc.M116.773176CrossRefPubMedPubMedCentralGoogle Scholar
  80. Sjöberg AP, Trouw LA, McGrath FDG et al (2006) Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol Baltim Md 1950 176:7612–7620.  https://doi.org/10.4049/jimmunol.176.12.7612CrossRefGoogle Scholar
  81. Skeie JM, Fingert JH, Russell SR et al (2010) Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci 51:5336–5342.  https://doi.org/10.1167/iovs.10-5322CrossRefPubMedPubMedCentralGoogle Scholar
  82. Slagman AC, Bock C, Abdel-Aty H et al (2011) Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model. Blood Purif 31:9–17.  https://doi.org/10.1159/000320763CrossRefPubMedGoogle Scholar
  83. Slevin M, Matou-Nasri S, Turu M et al (2010) Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol Zurich Switz 20:151–165.  https://doi.org/10.1111/j.1750-3639.2008.00256.xCrossRefGoogle Scholar
  84. Slevin M, Matou S, Zeinolabediny Y et al (2015) Monomeric C-reactive protein–a key molecule driving development of Alzheimer’s disease associated with brain ischaemia? Sci Rep 5:13281.  https://doi.org/10.1038/srep13281CrossRefPubMedPubMedCentralGoogle Scholar
  85. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314.  https://doi.org/10.1016/0092-8674(94)90337-9CrossRefPubMedGoogle Scholar
  86. Strang F, Scheichl A, Chen Y-C et al (2012) Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer’s disease? Brain Pathol Zurich Switz 22:337–346.  https://doi.org/10.1111/j.1750-3639.2011.00539.xCrossRefGoogle Scholar
  87. Suleiman M, Aronson D, Reisner SA et al (2003) Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 115:695–701.  https://doi.org/10.1016/j.amjmed.2003.06.008CrossRefPubMedGoogle Scholar
  88. Thiele JR, Habersberger J, Braig D et al (2014) Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation. in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation 130:35–50.  https://doi.org/10.1161/CIRCULATIONAHA.113.007124CrossRefPubMedGoogle Scholar
  89. Thiele JR, Zeller J, Kiefer J et al (2018) A conformational change in C-reactive protein enhances leukocyte recruitment and reactive oxygen species generation in ischemia/reperfusion injury. Front Immunol 9:675.  https://doi.org/10.3389/fimmu.2018.00675CrossRefPubMedPubMedCentralGoogle Scholar
  90. Thompson D, Pepys MB, Wood SP (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Struct Lond Engl 1993 7:169–177.  https://doi.org/10.1016/S0969-2126(99)80023-9CrossRefGoogle Scholar
  91. Tillett WS, Francis T (1930) Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 52:561–571.  https://doi.org/10.1084/jem.52.4.561CrossRefPubMedPubMedCentralGoogle Scholar
  92. van de Goot F, Krijnen PAJ, Begieneman MPV et al (2009) Acute inflammation is persistent locally in burn wounds: a pivotal role for complement and C-reactive protein. J Burn Care Res Off Publ Am Burn Assoc 30:274–280.  https://doi.org/10.1097/BCR.0b013e318198a252CrossRefGoogle Scholar
  93. Venugopal SK, Devaraj S, Jialal I (2005) Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166:1265–1271.  https://doi.org/10.1016/S0002-9440(10)62345-0CrossRefPubMedPubMedCentralGoogle Scholar
  94. Volanakis JE, Wirtz KW (1979) Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 281:155–157.  https://doi.org/10.1038/281155a0CrossRefPubMedGoogle Scholar
  95. Wang J, Gu BJ, Masters CL, Wang Y-J (2017) A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol 13:612–623.  https://doi.org/10.1038/nrneurol.2017.111CrossRefPubMedGoogle Scholar
  96. Wood JA, Wood PL, Ryan R et al (1993) Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 629:245–252.  https://doi.org/10.1016/0006-8993(93)91327-oCrossRefPubMedGoogle Scholar
  97. Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res 887:80–89.  https://doi.org/10.1016/s0006-8993(00)02970-xCrossRefPubMedGoogle Scholar
  98. Young DP, Kushner I, Samols D (2008) Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol Baltim Md 1950 181:2420–2427.  https://doi.org/10.4049/jimmunol.181.4.2420CrossRefGoogle Scholar
  99. Yousuf O, Mohanty BD, Martin SS et al (2013) High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol 62:397–408.  https://doi.org/10.1016/j.jacc.2013.05.016CrossRefPubMedGoogle Scholar
  100. Yuan X, Gu X, Crabb JS et al (2010) Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics MCP 9:1031–1046.  https://doi.org/10.1074/mcp.M900523-MCP200CrossRefPubMedGoogle Scholar
  101. Zacho J, Tybjaerg-Hansen A, Jensen JS et al (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359:1897–1908.  https://doi.org/10.1056/NEJMoa0707402CrossRefPubMedGoogle Scholar
  102. Zhang D, Sun M, Samols D, Kushner I (1996) STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 271:9503–9509.  https://doi.org/10.1074/jbc.271.16.9503CrossRefPubMedGoogle Scholar
  103. Zouki C, Haas B, Chan JS et al (2001) Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol Baltim Md 1950 167:5355–5361.  https://doi.org/10.4049/jimmunol.167.9.5355CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • James D. McFadyen
    • 1
    • 2
    • 3
    • 4
    Email author
  • Johannes Zeller
    • 5
  • Lawrence A. Potempa
    • 6
  • Geoffrey A. Pietersz
    • 1
    • 7
    • 8
  • Steffen U. Eisenhardt
    • 5
  • Karlheinz Peter
    • 1
    • 2
    • 7
    • 9
    Email author
  1. 1.Atherothrombosis and Vascular Biology LaboratoryBaker Heart and Diabetes InstituteMelbourneAustralia
  2. 2.Department of MedicineMonash UniversityMelbourneAustralia
  3. 3.Department of Clinical HaematologyThe Alfred HospitalMelbourneAustralia
  4. 4.Australian Centre for Blood Diseases, Monash UniversityMelbourneAustralia
  5. 5.Department of Plastic and Hand Surgery, Medical Faculty of the University of FreiburgUniversity of Freiburg Medical CentreFreiburgGermany
  6. 6.College of PharmacyRoosevelt UniversitySchaumburgUSA
  7. 7.Department of ImmunologyMonash UniversityMelbourneAustralia
  8. 8.Burnet InstituteMelbourneAustralia
  9. 9.Heart Centre, The Alfred HospitalMelbourneAustralia

Personalised recommendations